Catalent Biologics and Roche Announce Research Collaboration
The collaboration will focus on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
On Jan. 13, 2016 Catalent Biologics and Roche announced a collaboration to develop molecules coupling different therapeutic modalities using SMARTag technology, Catalent’s programmable protein-modification platform. According to the a press announcement from the companies,
Roche will gain non-exclusive access to the SMARTag platform and will have an option to take commercial licenses to develop molecules.The SMARTag platform will be combined with the hydrazino-Pictet-Spengler (HIPS) conjugation platform and will permit evaluation of alternative sites of drug conjugation.
Roche will pay Catalent an up-front fee of $1 million and provide additional research funding during the initial phase of the collaboration. Catalent has the potential to receive up to $618 million in development and commercial milestones, plus royalties on net sales of products, if Roche pursues commercial licenses and all options are exercised.
Source: Catalent
